- Created on the 20 March, 2017.
Receptor activator of nuclear factor kappa B (RANK) which is also referred to as TRANCE receptor, is a specific type I membrane protein which is mainly expressed on the surfaces of osteoclasts and is responsible for their activation following binding to the ligand. RANK is found to consist of 383 amino acids in its intracellular domain (from residues 234-616), also containing three putative TRAF-binding domains that are termed I, II, and III. It has the ability to interact with a number of different TRAFs using distinct motifs and can also activate NF-kappaB through a novel TRAF6 interaction motif. However, RANK can only activate JNK via a TRAF2-interacting region that is present in RANK.
Some of the important functions of RANK include being a key in the thermoregulation signalling in females (which is usually regulated by the ovarian sex hormones and expressed in regions of the brain linked with thermoregulation), is constitutively expressed in mammary epithelial tissues (where dysfunctional RANK leads to expansion and differentiation of the alveolar bunds into mature lobulo-alveolar and this causes disabling of milk production) and it has been reported to be expressed in some prostate and breast cancers. The standard used in the ELISA assay is a recombinant human RANK with the sequence of Q29-G213 amino acids. It is a di-polymer sequence made up of two chains and the molecular weight of 48 kDa each chain.
RANK ELISA kit is a protocol designed for analysing in vitro quantitative concentrations of receptor activator of nuclear factor kappa B (RANK)(TRANCE receptor) in human serum, cell culture supernatant and plasma. This assay has a minimum detection limit of < 2.0 pg/ml.
The minimum detection sensitivity level of RANK (TRANCE receptor) using this human RANK ELISA kit was 2.0 pg/ml. The dynamic assay range for this kit is 62.5 – 2,000 pg/ml.
- RANK ligand. Int J Biochem Cell Biol. (2007) 39 (6): 1077-81. Review. Blair J.M., et al.
- Multifunctional properties of RANKL/RANK in cell differentiation, proliferation and metastasis. Future Oncol. (2013) 9 (11): 1609-22. Review. Kukita A. and Kukita T.
- Clinical applications of RANK-ligand inhibition. Intern Med J. (2009) 39 (2): 110-6. Review. Romas E.
- RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol Metab. (2011) 22 (5): 188-94. Review. Schramek D., et al.
- Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis. Expert Opin Ther Targets. (2010) 14 (9): 923-34. Review. Jules J., et al.
- RANKL/RANK – from bone physiology to breast cancer. Cytokine Growth Factor Rev. (2014) 25 (2): 205-14. Review. Sigl V. and Penninger J.M.
- Full Name: Receptor Activator Nuclear Factor Kappa B (RANK) ELISA
- Reactivity: Human
- Sample Type: Serum, Cell Culture Supernatant, Plasma
- Sensitivity: < 2.0 pg/ml